| Volume: | 475,658 |
|---|---|
| Day's Low: | $41.26 |
| 52-wk Low: | $26.01 |
| Previous Close: | $40.96 |
| Dividend: | $0.00 |
| Market Cap: | NA |
| Avg Volume: | NA |
|---|---|
| Day's High: | $41.62 |
| 52-wk High: | $42.08 |
| Open Price: | $41.47 |
| Yield: | 0.00% |
| P/E (Forward): | NA |
| 7:16 PM | 11/23/2009 | UK's NICE Rejects Roche's Avastin In Bowel Cancer |
| 1:39 PM | 11/20/2009 | WHO: Mutated H1N1 Virus In Norway Sensitive To Antiviral Drugs |
| 1:21 AM | 11/20/2009 | Roche: Actemra Meets Endpoint In Arthritis In Children - Study |
| 4:54 PM | 11/18/2009 | UPDATE: FDA Panel Votes Against Approving Xolair In Children |
| 4:31 PM | 11/18/2009 | FDA Panel Split On Benefits of Genentech's Xolair For Children |
| 12:22 PM | 11/18/2009 | FDA Panel Questions Dosing Levels For Novartis's Xolair |
| 1:38 AM | 11/17/2009 | Roche: Additional Licence Application For Avastin Filed In US |
| 11/23/2009 | Europe drug stocks rally; Cephalon slides |
| 11/19/2009 | Senate bill weighs on Allergan, Medicis |
| 11/17/2009 | Alkermes gains; Cerus, InterMune tumble |
| 11/6/2009 | South Korean FDA Probes Roche for Aiding Tamiflu Stockpiling |
| 10/30/2009 | Drug stocks slip; Ipsen gains for second day |
| 10/27/2009 | By Paying More for a Drug, Medicare May Spend Less |
| 10/20/2009 | Gilead's earnings jump on strong drug sales |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | NA | NA | NA |
| EPS, GAAP | NA | NA | NA |
| Consensus Estimate | NA | NA | NA |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | NA | NA | NA |
| EPS, GAAP | NA | NA | NA |
| Consensus Estimate | NA | NA | NA |
| RHHBY | Industry Average | |
| P/E (TTM) | NA | NA |
| P/E (Forward) | NA | NA |
| PEG Ratio | NA | NA |
| Price/Sales | NA | NA |
| Beta | NA | NA |